Certified by Founder Lodge
AltPep
United States - Seattle, Washington
START UP
1 Disclosed Funding Rounds $53,000,000
0 Participating Investments
-
Founded date
2019
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
AltPep develops early disease-modifying treatments and detection tools for amyloid diseases by targeting one of the earliest molecular triggers – toxic soluble oligomers. These oligomers are
| Date | Round | Raised | Participating Investors |
|---|---|---|---|
| June, 26 ,2023 | Series B | $53,000,000 |
Eli Lilly and Company
S32
Senator Investment Group LP
IDRx
CAMP4 Therapeutics
Delfi Diagnostics
xilis
Manifold Bio
CRESS | $234,000 | (Feb 21, 2025)
Reverb Therapeutics | $21,000,000 | (Feb 21, 2025)
Safe Intelligence | $5,253,443 | (Feb 21, 2025)
EnPlusOne Biosciences | $10,000,000 | (Feb 21, 2025)
OpenEvidence | Undisclosed Amount | (Feb 21, 2025)
